Publications by authors named "A S Emirova"
Article Synopsis
- - Tanimilast, an inhaled phosphodiesterase-4 inhibitor, is being tested in phase 3 trials for COPD and asthma treatment, focusing on its pharmacokinetics and metabolite profiling.
- - Eight healthy male participants received a non-radiolabeled dose of tanimilast via inhaler, alongside an IV infusion of a labeled microtracer to analyze absorption, distribution, and elimination.
- - The study found that the inhaled form has about 50% bioavailability, with major drug elimination occurring via metabolism rather than urine, providing essential data for tanimilast's clinical development.
Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary disease (COPD) with this latter being the major cause of deaths. Despite differences in etiology and symptoms, a common feature of asthma and COPD is an underlying degree of airways inflammation.
View Article and Find Full Text PDFChronic obstructive pulmonary disease (COPD) patients with higher eosinophil counts are associated with increased clinical response to phosphodiesterase-4-inhibitors (PDE4i). However, the underlying inflammatory mechanisms associated with this increased response is not yet elucidated. This post hoc analysis focused on sputum gene expression in patients with chronic bronchitis who underwent 32-day treatment with two doses of the inhaled PDE4i CHF6001 (tanimilast) or placebo on top of triple therapy.
View Article and Find Full Text PDFBackground: This study evaluated the efficacy, safety and tolerability of the novel inhaled phosphodiesterase-4 inhibitor CHF6001 added-on to formoterol in patients with chronic obstructive pulmonary disease (COPD).
Methods: Randomised, double-blind, placebo- and active-controlled, parallel-group study. Eligible patients had symptomatic COPD, post-bronchodilator forced expiratory volume in 1 s (FEV) 30-70% predicted, and history of ≥1 moderate/severe exacerbation.